Literature DB >> 25611179

Prognostic impact of lymph node metastasis in distal cholangiocarcinoma.

M Kiriyama1, T Ebata, T Aoba, Y Kaneoka, T Arai, Y Shimizu, M Nagino.   

Abstract

BACKGROUND: The aim of the study was to investigate the prognostic impact of lymph node metastasis in cholangiocarcinoma using three different classifications.
METHODS: Patients who underwent pancreaticoduodenectomy for distal cholangiocarcinoma in 24 hospitals in Japan between 2001 and 2010 were included. Survival was calculated by means of the Kaplan-Meier method and differences between subgroups were assessed with the log rank test. The Cox proportional hazards model was used to identify independent predictors of survival. χ(2) scores were calculated to determine the cut-off value of the number of involved nodes, lymph node ratio (LNR) and total lymph node count (TLNC) for discriminating survival.
RESULTS: Some 370 patients were included. The median (range) TLNC was 19 (3-59). Nodal metastasis occurred in 157 patients (42·4 per cent); the median (range) number of involved nodes and LNR were 2 (1-19) and 0·11 (0·02-0·80) respectively. Four or more involved nodes was associated with a significantly shorter median survival (1·3 versus 2·2 years; P = 0·001), as was a LNR of at least 0·17 (1·4 versus 2·3 years; P = 0·002). Involvement of nodes along the common hepatic artery, present in 21 patients (13·4 per cent), was also associated with a shorter survival (median 1·3 versus 2·1 years; P = 0·046). Multivariable analysis among 157 node-positive patients identified the number of involved nodes as an independent prognostic factor (risk ratio 1·87; P = 0·002).
CONCLUSION: The number of involved nodes was a strong predictor of survival in patients with distal cholangiocarcinoma.
© 2015 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2015        PMID: 25611179     DOI: 10.1002/bjs.9752

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  37 in total

1.  Percutaneous biliary drainage is oncologically inferior to endoscopic drainage: a propensity score matching analysis in resectable distal cholangiocarcinoma.

Authors:  Kenichi Komaya; Tomoki Ebata; Yasuyuki Fukami; Eiji Sakamoto; Hideo Miyake; Daisuke Takara; Kenji Wakai; Masato Nagino
Journal:  J Gastroenterol       Date:  2015-11-09       Impact factor: 7.527

2.  Survival outcome and prognostic factors after pancreatoduodenectomy for distal bile duct carcinoma: a retrospective multicenter study.

Authors:  Ekaterina Petrova; Felix Rückert; Sebastian Zach; YinFeng Shen; Jürgen Weitz; Robert Grützmann; Uwe A Wittel; Frank Makowiec; Ulrich T Hopt; Peter Bronsert; Florian Kühn; Bettina M Rau; Roman E Izrailov; Igor E Khatkov; Hryhoriy Lapshyn; Louisa Bolm; Dirk Bausch; Tobias Keck; Ulrich F Wellner; Gabriel Seifert
Journal:  Langenbecks Arch Surg       Date:  2017-06-13       Impact factor: 3.445

3.  Pancreaticoduodenectomy for distal cholangiocarcinoma: surgical results, prognostic factors, and long-term follow-up.

Authors:  Stefano Andrianello; Salvatore Paiella; Valentina Allegrini; Marco Ramera; Alessandra Pulvirenti; Giuseppe Malleo; Roberto Salvia; Claudio Bassi
Journal:  Langenbecks Arch Surg       Date:  2015-07-02       Impact factor: 3.445

4.  Impact of adjuvant chemotherapy after pancreaticoduodenectomy for distal cholangiocarcinoma: a propensity score analysis from a French multicentric cohort.

Authors:  Damien Bergeat; Olivier Turrini; Laetitia Courtin-Tanguy; Stéphanie Truant; Benjamin Darnis; Jean Robert Delpero; Jean-Yves Mabrut; Nicolas Regenet; Laurent Sulpice
Journal:  Langenbecks Arch Surg       Date:  2018-08-15       Impact factor: 3.445

5.  Relationship between the surgical margin status, prognosis, and recurrence in extrahepatic bile duct cancer patients.

Authors:  Hiroshi Kurahara; Kosei Maemura; Yuko Mataki; Masahiko Sakoda; Satoshi Iino; Yota Kawasaki; Shinichiro Mori; Yuko Kijima; Shinichi Ueno; Hiroyuki Shinchi; Sonshin Takao; Shoji Natsugoe
Journal:  Langenbecks Arch Surg       Date:  2016-08-05       Impact factor: 3.445

Review 6.  The survival outcome and prognostic factors for distal cholangiocarcinoma following surgical resection: a meta-analysis for the 5-year survival.

Authors:  U F Wellner; YinFeng Shen; T Keck; WenYin Jin; Ze Xu
Journal:  Surg Today       Date:  2016-05-28       Impact factor: 2.549

7.  Over 700 Whipples for Pancreaticobiliary Malignancies: Postoperative Morbidity Is an Additional Negative Prognostic Factor for Distal Bile Duct Cancer.

Authors:  Stefano Andrianello; Giovanni Marchegiani; Giuseppe Malleo; Borislav Chavdarov Rusev; Aldo Scarpa; Deborah Bonamini; Laura Maggino; Claudio Bassi; Roberto Salvia
Journal:  J Gastrointest Surg       Date:  2016-11-23       Impact factor: 3.452

Review 8.  Multimodality Management of Localized Biliary Cancer.

Authors:  Nadia Ashai; Preethi Prasad; Lakshmi Rajdev
Journal:  Curr Treat Options Oncol       Date:  2019-05-29

9.  Resected pN1 non-small cell lung cancer: recurrence patterns and nodal risk factors may suggest selection criteria for post-operative radiotherapy.

Authors:  Paolo Borghetti; Fernando Barbera; Marco Lorenzo Bonù; Francesca Trevisan; Stefano Ciccarelli; Paola Vitali; Marta Maddalo; Luca Triggiani; Nadia Pasinetti; Sara Pedretti; Bartolomea Bonetti; Gianluca Pariscenti; Andrea Tironi; Alberto Caprioli; Michela Buglione; Stefano Maria Magrini
Journal:  Radiol Med       Date:  2016-05-26       Impact factor: 3.469

10.  Proposal for a new T-stage classification system for distal cholangiocarcinoma: a 10-institution study from the U.S. Extrahepatic Biliary Malignancy Consortium.

Authors:  Lauren M Postlewait; Cecilia G Ethun; Nina Le; Timothy M Pawlik; Stefan Buettner; George Poultsides; Thuy Tran; Kamran Idrees; Chelsea A Isom; Ryan C Fields; Bradley Krasnick; Sharon M Weber; Ahmed Salem; Robert C G Martin; Charles Scoggins; Perry Shen; Harveshp D Mogal; Carl Schmidt; Eliza Beal; Ioannis Hatzaras; Gerardo Vitiello; Kenneth Cardona; Shishir K Maithel
Journal:  HPB (Oxford)       Date:  2016-08-09       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.